Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Intercure Ltd. Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.	Israel	INCR
Intercure Ltd. A leading producer of pharmaceutical-grade, GMP-certified medical cannabis products.	United States of America	INCR
Intervacc AB Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.	Sweden	IVACC
iNtRON Biotechnology, Inc. Develops phage therapeutics and molecular diagnostics to combat infectious diseases.	South Korea	048530
Inventage Lab Inc. Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.	South Korea	389470
Inventiva S.A. Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.	United States of America	IVA
Invivyd, Inc. Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.	United States of America	IVVD
IO Biotech, Inc. Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.	United States of America	IOBT
IONIS PHARMACEUTICALS INC A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.	United States of America	IONS
IOVANCE BIOTHERAPEUTICS, INC. Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.	United States of America	IOVA